Table 1.

Treatment responses of bortezomib on human patients

Patient number	Trial start	Trial stop	cGVHD organs	Immunosuppression before trial	Immunosuppression at conclusion of the study	cGVHD score before start of the trial	cGVHD score at conclusion of the study	Comments
1	10/16/12	4/10/13	Steroid refractory ophthalmic GVHD, mouth	Cyclosporine ophthalmic drop	Cyclosporine ophthalmic drop	Eyes 3	Eyes 1	Restarted on bortezomib 6 mo after the completion of the study due to relapse of cGVHD.
						Mouth 1	Mouth 0
2	11/20/12	1/15/13	Eyes, mouth, skin	Mycophenolate 100 mg twice daily, tacrolimus 1 mg daily, sirolimus 1 mg twice daily, prednisone 20 mg alternating with 40 mg	Mycophenolate 100 mg twice daily, tacrolimus 1 mg daily, sirolimus 1 mg twice daily, prednisone 20 mg alternating with 40 mg	Mouth 3	Mouth 3	Early withdrawal due to mouth sores.
						Joints 3	Joints 3
						Skin 2	Skin 2
3	01/14/13	05/07/13	Skin, mouth, eyes, GI, lungs, joints, and fascia	Mycophenolate 1000 mg twice daily and prednisone 40 mg qod	Mycophenolate 1000 mg twice daily and prednisone 40 mg qod	2 for all organs involved	2 for all organs involved	No significant response was observed
4	03/18/13	08/27/13	Skin, GI, mouth, and joint	Tacrolimus 1.5 mg twice daily, mycophenolate 1 g twice daily, prednisone 40 mg/day	Tacrolimus 1.5 mg twice daily, Mycophenolate 1 g twice daily, prednisone 30 mg/day	Skin 3	Skin 2	Significant healing of the ulcerated skin and mild softening/ decrease in pigmentation. Improved swallowing
						GI 2	GI 1
						Mouth 3	Mouth 2
						Joint 3	Joint 2
5	06/25/13	12/10/13	Steroid-dependent hemolytic anemia, mouth, and eye	Prednisone 60 mg/day and tacrolimus 1 mg a day alternating with 0.5 mg/day	Prednisone 0.5 mg 3 times a week	Anemia: severe	Anemia: mild	Restarted on bortezomib, 4 mo after the completion of the study to maintain the response
						Mouth 1	Mouth 0
						Eye 1	Eye 0
6	08/02/13	09/03/13	Steroid-refractory skin	Tacrolimus 1.5 mg twice daily	Tacrolimus 1.5 mg twice daily	Skin 3	Skin 3	Withdrawn from the study after one month due to relapse of the chronic myelomonocytic leukemia
7	08/13/13	01/07/14	Skin, eyes, and mouth	Tacrolimus 0.5 mg thrice daily, Sirolimus 1 mg daily, prednisone 30 mg daily	Tacrolimus 0.5 mg twice daily, prednisone 15 mg alternating with 5 mg daily	Skin 2	Skin 1	Responding but withdrawn early from the study due to neuropathy
						Eyes 2	Eyes 1
						Mouth 0	Mouth 0
8	09/17/13	11/05/13	Skin, mouth, and lung	Prednisone 30 mg daily, sirolimus 1 mg three times a week	Prednisone 15 mg daily alternating with 10 mg a day; tacrolimus 0.5 mg twice a day	Skin 3	Skin 2	Withdrawn early from the study due to symptomatic respiratory infections and hospital admissions
						Mouth 2	Mouth 1
						Lung 3	Lung 3
9	09/20/13	03/14/14	Skin, mouth, eyes, and liver	Cyclosporine 25 mg 3 times a week and prednisone 30 mg daily	None	Mouth 2	Mouth 0	Relapse of GVHD 4 mo after the last dose of the study drug
						Eye 2	Eye 1
						Skin 1	Skin 0
10	12/6/13	1/24/14	Steroid-intolerant and -dependent skin, mouth, and eyes	Prednisone 20 mg qod and cyclosporine 25 mg daily.	Prednisone 20mg qod and cyclosporine 25 mg daily.	Skin 3	Skin 3	Withdrawn early from the study due to low platelets
						Mouth 2	Mouth 2

qod, every other day.